Xenon Pharmaceuticals Inc. (XENE): Price and Financial Metrics


Xenon Pharmaceuticals Inc. (XENE): $26.53

-0.26 (-0.97%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add XENE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 476

in industry

XENE POWR Grades


  • Sentiment is the dimension where XENE ranks best; there it ranks ahead of 66.63% of US stocks.
  • XENE's strongest trending metric is Momentum; it's been moving down over the last 52 weeks.
  • XENE ranks lowest in Stability; there it ranks in the 6th percentile.

XENE Stock Summary

  • XENE's price/sales ratio is 69.63; that's higher than the P/S ratio of 96.18% of US stocks.
  • With a year-over-year growth in debt of 313.78%, Xenon Pharmaceuticals Inc's debt growth rate surpasses 96.42% of about US stocks.
  • Revenue growth over the past 12 months for Xenon Pharmaceuticals Inc comes in at -34.59%, a number that bests only 5.79% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Xenon Pharmaceuticals Inc are SGMO, PTGX, ENTA, ORMP, and NRIX.
  • Visit XENE's SEC page to see the company's official filings. To visit the company's web site, go to www.xenon-pharma.com.

XENE Valuation Summary

  • XENE's price/sales ratio is 39.7; this is 249.78% higher than that of the median Healthcare stock.
  • Over the past 83 months, XENE's EV/EBIT ratio has gone down 20.2.
  • XENE's price/sales ratio has moved up 34.4 over the prior 83 months.

Below are key valuation metrics over time for XENE.

Stock Date P/S P/B P/E EV/EBIT
XENE 2021-08-31 39.7 2.8 -12.6 -10.9
XENE 2021-08-30 38.0 2.7 -12.1 -10.3
XENE 2021-08-27 39.1 2.8 -12.4 -10.7
XENE 2021-08-26 38.2 2.7 -12.2 -10.4
XENE 2021-08-25 38.2 2.7 -12.2 -10.4
XENE 2021-08-24 38.2 2.7 -12.2 -10.4

XENE Growth Metrics

  • The year over year revenue growth rate now stands at 111.74%.
  • Its year over year price growth rate is now at 29.27%.
  • Its 4 year net cashflow from operations growth rate is now at 48.39%.
Over the past 33 months, XENE's revenue has gone up $19,850,000.

The table below shows XENE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 19.85 -61.906 -63.985
2021-06-30 18.28 -58.053 -57.507
2021-03-31 29.446 -55.765 -36.089
2020-12-31 32.166 -48.124 -28.013
2020-09-30 30.345 -15.275 -26.991
2020-06-30 27.291 -11.188 -26.921

XENE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XENE has a Quality Grade of D, ranking ahead of 7.55% of graded US stocks.
  • XENE's asset turnover comes in at 0.077 -- ranking 283rd of 681 Pharmaceutical Products stocks.
  • ADMP, ACUR, and ELTP are the stocks whose asset turnover ratios are most correlated with XENE.

The table below shows XENE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.077 1 -0.353
2021-03-31 0.132 1 -0.233
2020-12-31 0.154 1 -0.194
2020-09-30 0.153 1 -0.197
2020-06-30 0.157 1 -0.237
2020-03-31 0.094 1 -0.381

XENE Price Target

For more insight on analysts targets of XENE, see our XENE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $27.88 Average Broker Recommendation 1.17 (Strong Buy)

XENE Stock Price Chart Interactive Chart >

Price chart for XENE

XENE Price/Volume Stats

Current price $26.53 52-week high $36.42
Prev. close $26.79 52-week low $10.86
Day low $25.75 Volume 464,557
Day high $27.63 Avg. volume 732,683
50-day MA $28.42 Dividend yield N/A
200-day MA $20.70 Market Cap 1.37B

Xenon Pharmaceuticals Inc. (XENE) Company Bio


Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing differentiated therapeutics for orphan indications in Canada. The company was founded in 1996 and is based in Burnaby, Canada.


XENE Latest News Stream


Event/Time News Detail
Loading, please wait...

XENE Latest Social Stream


Loading social stream, please wait...

View Full XENE Social Stream

Latest XENE News From Around the Web

Below are the latest news stories about Xenon Pharmaceuticals Inc that investors may wish to consider to help them evaluate XENE as an investment opportunity.

SVB Leerink Weighs in on Xenon Pharmaceuticals Inc.s FY2021 Earnings (NASDAQ:XENE)

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Research analysts at SVB Leerink dropped their FY2021 earnings estimates for shares of Xenon Pharmaceuticals in a research report issued on Wednesday, November 10th. SVB Leerink analyst M. Goodman now anticipates that the biopharmaceutical company will earn ($1.60) per share for the year, down from their previous estimate of ($1.50). []

Dakota Financial News | November 17, 2021

Xenon Pharmaceuticals Insider Sold Over $550K In Company Stock

Simon Pimstone, Insider at Xenon Pharmaceuticals (NASDAQ:XENE), made a large insider sell on November 15, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Pimstone sold 17,557 shares of Xenon Pharmaceuticals at a price of $31.33. The total transaction amounted to $550,061. Pimstone still owns a total of 210,186 shares of Xenon Pharmaceuticals worth, $6,568,312. Xenon Pharmaceuticals shares are trading down 2.31%

Yahoo | November 17, 2021

Insider Selling: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Sells 17,557 Shares of Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Simon N. Pimstone sold 17,557 shares of Xenon Pharmaceuticals stock in a transaction on Monday, November 15th. The stock was sold at an average price of $31.33, for a total value of $550,060.81. The transaction was disclosed in a document filed with the SEC, which is available through this link. []

Dakota Financial News | November 16, 2021

Wedbush Research Analysts Lift Earnings Estimates for Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Investment analysts at Wedbush upped their FY2021 earnings per share estimates for shares of Xenon Pharmaceuticals in a research note issued on Thursday, November 11th. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will post earnings per share of ($1.79) for the year, up from their previous estimate […]

Dakota Financial News | November 16, 2021

Analysts Offer Predictions for Xenon Pharmaceuticals Inc.s FY2021 Earnings (NASDAQ:XENE)

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Investment analysts at William Blair upped their FY2021 earnings per share (EPS) estimates for shares of Xenon Pharmaceuticals in a note issued to investors on Wednesday, November 10th. William Blair analyst T. Lugo now expects that the biopharmaceutical company will earn ($1.54) per share for the year, up from their []

Dakota Financial News | November 15, 2021

Read More 'XENE' Stories Here

XENE Price Returns

1-mo -14.83%
3-mo 46.17%
6-mo 42.94%
1-year 123.13%
3-year 214.71%
5-year 233.71%
YTD 72.50%
2020 17.32%
2019 107.77%
2018 123.36%
2017 -63.31%
2016 -4.23%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8147 seconds.